Evonik, a global specialty chemicals company, and Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, have entered a strategic collaboration to develop and market a novel lipid nanoparticle (LNP) platform for nucleic acid delivery. Through this collaboration, Evonik will expand its offering of formulation development services to customers with Ethris’ lipidoid nanoparticle (SNaP LNP) technology platform. Ethris will leverage Evonik’s expert...